PROJECT TITLE: Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Pancreatic Tumors PROJECT SUMMARY: The development of tools for the targeted delivery of Imaging-probes and therapeufic agents has become the focus of intense efforts in the context of many human diseases. The in vivo screening method in which phage can be selected from engineered combinatorial peptide libraries for their ability to target specific vascular beds has uncovered a vascular address system that allows specific angiogenesis-related targeting to blood vessels in cancer. This phage display-based targeting Is expanded by the direct-assembly of gold and nanoporous silicon nanoparticles onto phage for nanomedical applications. Through exploiting the nanodimensions of the phage particle as a molecular network we generated biologically active nanoassemblies (NAs) with concomitant unique and tunable chemical and physical properties. These properties include near-infrared (NIR) radiation conversion to heat, enhancement of fluorescent signals, NIR surface enhanced Raman scattering (SERS) and the ability to conjugate and incorporate therapies or imaging-tracers. This tuning capability combined with the programmable tissue targefing affords the Integrafion of multiple funcfionalities into a single NA and serves as a complementary and non-mutually exclusive tool among different applicafions, including chemotherapy targeting and molecular imaging. Project 4 aims to develop the ligand-directed Si particles- phage- Au particles NAs as novel systems for targeted imaging and therapy in endocrine pancreatic tumors. These efforts will be translated into wide-ranging clinical applicafions

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151668-04
Application #
8549995
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$228,173
Indirect Cost
$25,560
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Zacharias, Niki; Lee, Jaehyuk; Ramachandran, Sumankalai et al. (2018) Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol :
Hövener, Jan-Bernd; Pravdivtsev, Andrey N; Kidd, Bryce et al. (2018) Parahydrogen-Based Hyperpolarization for Biomedicine. Angew Chem Int Ed Engl 57:11140-11162
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167
Khalid, Ayesha; Persano, Stefano; Shen, Haifa et al. (2017) Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert Opin Drug Deliv 14:865-877
Venuta, Alessandro; Wolfram, Joy; Shen, Haifa et al. (2017) Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B 5:207-219
Kanlikilicer, Pinar; Ozpolat, Bulent; Aslan, Burcu et al. (2017) Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262
Rodriguez-Aguayo, Cristian; Monroig, Paloma Del C; Redis, Roxana S et al. (2017) Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029

Showing the most recent 10 out of 332 publications